Prosecution Insights
Last updated: April 19, 2026

ICELL GENE THERAPEUTICS INC.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17878339 CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF PRIEST, AARON A 1681 Non-Final OA Aug 01, 2022
17735197 COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF BRISTOL, LYNN ANNE 1643 Non-Final OA May 03, 2022
17590983 CHIMERIC ANTIGEN RECEPTORS AND ENHANCEMENT OF ANTI-TUMOR ACTIVITY BRISTOL, LYNN ANNE 1643 Final Rejection Feb 02, 2022
17502238 Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof BRISTOL, LYNN ANNE 1643 Non-Final OA Oct 15, 2021

Managing ICELL GENE THERAPEUTICS INC.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month